The future of drug discovery: Enabling technologies for enhancing lead characterization and profiling therapeutic potential

Expert Opinion on Drug Discovery

Volumn 9, Issue 8, 2014, Pages 847-858

  Janero, David R ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Activity based protein profiling; Disease models; Drug targets; Enzymes; Functional proteomics; Genome editing; Lead profiling; Ligand interaction; Molecular pharmacology; Nucleases; Protein dynamics; Receptors; Structural biology

Indexed keywords

NUCLEASE; PROTEOME; PROTEIN;

BIOTECHNOLOGY; DEUTERIUM HYDROGEN EXCHANGE; DRUG INDUSTRY; DYNAMICS; GENOME; LIGAND BINDING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; METABOLISM; PHARMACEUTICS; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; MODELS, BIOLOGICAL; PROTEINS; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84904816466     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.925876     Document Type: Review

References (99)

1. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19
2. Janero DR. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca. Expert Opin Drug Discov 2012;7:449-56
3. Jarvis LM. The year in new drugs. Chem Eng News 2014;92:10-13
4. Jacunski A, Tatonetti NP. Connecting the dots: applications of network medicine in pharmacology and disease. Clin Pharmacol Ther 2013;94:659-69
5. Kenakin T, Bylund DB, Toews ML, et al. Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century. Biochem Pharmacol 2014;87:64-77
6. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51
7. Bhogal N, Balls M. Translation of new technologies: from basic research to drug discovery and development. Curr Drug Discov Technol 2008;5:250-62
8. Benovic JL. G-protein-coupled receptors signal victory. Cell 2012;151:1148-50
9. Zheng H, Hou J, Zimmerman MD, et al. The future of crystallography in drug discovery. Expert Opin Drug Discov 2014;9:125-37
10. Kang HJ, Lee C, Drew D. Breaking the barriers in membrane protein crystallography. Int J Biochem Cell Biol 2013;45:636-44
11. Topiol S. X-Ray structural information of GPCRs in drug design: what are the limitations and where do we go? Expert Opin Drug Discov 2013;8:607-20
12. Preininger AM, Meiler J, Hamm HE. Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. J Mol Biol 2013;425:2288-98
13. Schramm VL. Transition states, analogues, and drug development. ACS Chem Biol 2013;8:71-81
14. Marcsisin SR, Engen JR. Hydrogen exchange mass spectrometry: what is it and what can it tell us? Anal Bioanal Chem 2010;397:967-72
15. Wei H, Mo J, Russell RJ, et al. Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov Today 2014;19:95-102
16. Jaswal SS. Biological insights from hydrogen exchange mass spectrometry. Biochim Biophys Acta 2013;1834:1188-201
17. Landgraf RR, Chalmers MJ, Griffin PR. Automated hydrogen/deuterium exchange electron transfer dissociation high resolution mass spectrometry measured at single-amide resolution. J Am Soc Mass Spectrom 2012;23:301-9
18. Resetca D, Wilson DJ. Characterizing rapid, activity-linked conformational transitions in proteins via sub-second hydrogen deuterium exchange mass spectrometry. FEBS J 2013;280:5616-25
19. Iacob RE, Engen JR. Hydrogen exchange mass spectrometry: are we out of quicksand? J Am Soc Mass Spectrom 2012;23:1003-10
20. Balasubramaniam D, Komives EA. Hydrogen-exchange mass spectrometry for the study of intrinsic disorder in proteins. Biochim Biophys Acta 2013;1834:1202-9
21. Shan Y, Arkhipov A, Kim ET, et al. Transitions to catalytically inactive conformations in EGFR kinase. Proc Natl Acad Sci USA 2013;110:7270-5
22. Karageorgos I, Wales TE, Janero DR, et al. Active-site inhibitors modulate the dynamic properties of human monoacylglycerol lipase: a hydrogen exchange mass spectrometry study. Biochemistry 2013;52:5016-26
23. Nasr ML, Shi X, Bowman AL, et al. Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire. Protein Sci 2013;22:774-87
24. Yu W, Chory EJ, Wernimont AK, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012;3:1-11
25. Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed 2014;53:199-204
26. Sowole MA, Alexopoulos JA, Cheng YQ, et al. Activation of ClpP protease by ADEP antibiotics: insights from hydrogen exchange mass spectrometry. J Mol Biol 2013;425:4508-19
27. Boerma LJ, Xia G, Qui C, et al. Defining the communication between agnostic and coactivator binding in the retinoid x receptor alpha ligand binding domain. J Biol Chem 2014;289:814-26
28. Ahmed AH, Ptak CP, Fenwick MK, et al. Dynamics of cleft closure of the GluA2 ligand-binding domain in the presence of full and partial agonists revealed by hydrogen-deuterium exchange. J Biol Chem 2013;288:27658-66
29. West GM, Chien EY, Katritch V, et al. Ligand-dependent perturbation of the conformational ensemble for the GPCR b2 adrenergic receptor revealed by HDX. Structure 2011;19:1424-32
30. Tiyanont K, Wales TE, Siebel CW, et al. Insights into Notch3 activation and inhibition mediated by antibodies directed against its negative regulatory region. J Mol Biol 2013;425:3192-204
31. Iacob RE, Bou-Assaf GM, Makowski L, et al. Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements. J Pharm Sci 2013;102:4315-29
32. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013;12:205-16
33. Zhang J, Chalmers MJ, Stayrook KR, et al. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure 2010;18:1332-41
34. Wang K, Yang T, Wu Q, et al. Chemistry-based functional proteomics for drug target deconvolution. Expert Rev Proteomics 2012;9:293-310
35. Copley SD. Toward a systems biology perspective on enzyme evolution. J Biol Chem 2012;287:3-10
36. Simon GM, Cravatt BF. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. J Biol Chem 2010;285:11051-5
37. Nodwell MB, Sieber SA. ABPP methodology: introduction and overview. Top Curr Chem 2012;324:1-42
38. Li N, Overkleeft HS, Florea BI. Activity-based protein profiling: an enabling technology in chemical biology research. Curr Opin Chem Biol 2012;16:227-33
39. Wang R, Borazjani A, Matthews AT, et al. Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme. Biochemistry 2013;52:7559-74
40. Wang C, Weerapana E, Blewett MM, et al. A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles. Nat Methods 2014;11:79-85
41. Nan L, Kuo CL, Paniagua G, et al. Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. Nat Protoc 2013;8:1155-68
42. Moellering RE, Cravatt BF. Functional lysine modification by an intrinsically reactive primary glycolytic metabolite. Science 2013;341:549-53
43. Krysiak J, Breinbauer R. Activity-based protein profiling for natural product target discovery. Top Curr Chem 2012;324:43-84
44. Bottcher T, Pitscheider M, Sieber SA. Natural products and their biological targets: proteomic and metabolomic labeling strategies. Angew Chem Int Ed 2010;49:2680-98
45. Nomure DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer 2010;10:630-8
46. Chang JW, Cognetta AB, Niphakis MJ, et al. Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition. ACS Chem Biol 2013;8:1590-9
47. Ward J, Spath SN, Pabst B, et al. Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry-activity-based protein profiling. Biochemistry 2013;52:9187-201
48. Dominguez E, Galmozzi A, Chang JW, et al. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nat Chem Biol 2014;10:113-21
49. Lian J, Quiroga AD, Li L, et al. Ces3/TGH deficiency improves dyslipidemia and reduces atherosclerosis in Ldlr-/-mice. Circ Res 2012;111:982-90
50. Lin JH. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr Drug Metab 2008;9:419-38
51. van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med 2010;7:e10000245
52. Breyer MD. Improving productivity of modern-day drug discovery. Expert Opin Drug Discov 2014;9:115-18
53. Hongmei LL, Nakano T, Hotta A. Genetic correction using engineered nucleases for gene therapy applications. Dev Growth Differ 2014;56:63-77
54. Tan W, Carlson DF, Walton MW, et al. Precision editing of large animal genomes. Adv Genet 2012;80:37-97
55. Sakuma T, Woltjen K. Nuclease-mediated genome editing: at the front-line of functional genomics technology. Dev Growth Differ 2014;56:2-13
56. Perez-Pinera P, Ousterout DG, Gersbach CA. Advances in targeted genome editing. Curr Opin Chem Biol 2012;16:268-77
57. Sun N, Zhao H. Transcription activatorlike effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioeng 2013;110:1811-21
58. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 2013;10:957-63
59. Mashimo T. Gene targeting technologies in rats: zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats. Dev Growth Differ 2014;56:46-52
60. Wirt SE, Porteus MH. Development of nuclease-mediated site-specific genome modification. Curr Opin Immunol 2012;24:609-16
61. Wei C, Liu J, Yu Z, et al. TALEN or Cas9-Rapid, efficient and specific choices for genome modifications. J Genet Genomics 2013;40:281-9
62. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31:397-405
63. Musunuru K. Genome editing of human pluripotent stem cells to generate human cellular disease models. Dis Model Mech 2013;6:896-904
64. Reinhardt P, Schmid B, Burbulla LF, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013;12:354-67
65. Toscano MG, Anderson P, Munoz P, et al. Use of zinc-finger nucleases to knock out the WAS gene in K562 cells: a human cellular model for Wiskott-Aldrich syndrome. Dis Model Mech 2013;6:544-54
66. Zhang X, Li H, Mao Y, et al. An over expression APP model for anti-Alzheimer disease drug acreening created by zinc finger nuclease technology. PLoS One 2013;8:e75493
67. Frank S, Skryabin BV, Greber B. A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models. BMC Genomics 2013;14:773
68. Voit RA, Hendel A, Pruett-Miller SM, et al. Nuclease-mediated gene editing by homologous recombination of the human globin locus. Nucleic Acids Res 2014;42:1365-78
69. Ochiai H, Miyamoto T, Kanai A, et al. TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. Proc Natl Acad Sci USA 2014;111:1461-6
70. Horii T, Tamura D, Morita S, et al. Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system. Int J Mol Sci 2013;14:19774-81
71. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014;343:84-7
72. Wang T, Wei JJ, Sabatini DM, et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014;343:80-4
73. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011;475:217-21
74. Watanabe M, Nakano K, Matsunari H, et al. Generation of interleukin-2 receptor gamma gene knockout pigs from somatic cells genetically modified by zinc finger nuclease-encoding mRNA. PLoS One 2013;8:e76478
75. Ferguson C, McKay M, Harris RA, et al. Toll-like receptor 4 (Tlr4) knockout rats produced by transcriptional activator-like effector nuclease (TALEN)-mediated gene inactivation. Alcohol 2013;47:595-9
76. Carlson DF, Tan W, Lillico SG, et al. Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci USA 2012;109:17382-7
77. Wefers B, Meyer M, Ortiz O, et al. Direct production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides. Proc Natl Acad Sci USA 2013;110:3782-7
78. Tan W, Carlson DF, Lancto CA, et al. Efficient nonmeiotic allele introgression in livestock using custom endonucleases. Proc Natl Acad Sci USA 2013;110:16526-31
79. Zhou J, Shen B, Zhang W, et al. One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. Int J Biochem Cell Biol 2014;46:49-55
80. Niu Y, Shen B, Cui Y, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014;156:1-8
81. Townes CN. The first laser. In: Garwin L, Lincoln T, editors, A century of Nature: twenty-one discoveries that changed science and the world. University of Chicago Press, Chicago, USA; 2003. p. 107-12
82. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011;10:712-13
83. Sacks LV, Shamsuddin HH, Yasinkaya YI, et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 2014;311:378-84
84. Patel AC. Clinical relevance of target identity and biology: implications for drug discovery and development. J Biomol Screen 2013;18:1164-85
85. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014. [Epub ahead of print]
86. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-10
87. Szymanski DW, Papanastasiou M, Melchior K, et al. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. J Proteome Res 2011;10:4789-98
88. Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications, and challenges. Hum Mol Genet 2014. [Epub ahead of print]
89. Sternberg SH, Redding S, Jinek M, et al. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 2014;507:62-7
90. Jinek M, Jiang F, Taylor DW, et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 2014;343(6176):1247997
91. Owens B. Zinc-finger nucleases make the cut in HIV. Nat Rev Drug Discov 2014;13:321-2
92. Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013;27:495-507
93. Englander SW. Hydrogen exchange and mass spectrometry: a historical perspective. J Am Soc Mass Spectrom 2006;17:1481-9
94. Jessani M, Cravatt BF. The development and application of methods for activity-based protein profiling. Curr Opin Chem Biol 2004;8:54-9
95. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339:819-23
96. Department of Health and Human Services. Shared instrumentation grant program. 2014. Available from: www.grants.nih.gov/grants/guide/pa-files/PAR-13- 008.html [Last accessed 14 May 2014]
97. Department of Health and Human Services. Instrument development for biomedical applications. 2012. Available from: www.grants.nih.gov/grants/guide/ rfa-files/PAR-RR-11-00 5. html [Last accessed 14 May 2014]
98. Wellcome Trust. Biomedical resource and technology development grants. 2014. Available from: www.wellcome.ac. uk/Funding/Biomedical-science/Funding- schemes/Strategic-awards-and-initiatives/WTDV031727.htm [Last accessed 14 May 2014]
99. Shen H. CRISPR technology leaps from lab to industry. Nature. 2013. Available from: www.natutre.com/news/cripsr-technoilogy-leaps-from-lab-to- industry-1.14299 [Last accessed 14 May 2014]